RDWM
PLX icon

Red Door Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Red Door Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$3K – 477
2021
Q2 		$3K Buy
+2,000
New +$6.88K ﹤0.01% 546

Other funds holding PLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Red Door Wealth Management's PLX Position: Q3 2021 in Review

Red Door Wealth Management sold out of Protalix BioTherapeutics (PLX) in Q3 2021, closing a stake of 2,000 shares — an estimated $3K sold.

Red Door Wealth Management first reported a position in PLX in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 34 funds tracked by Wall St. Rank hold PLX as of Q3 2021.

  • Red Door Wealth Management reported no remaining Protalix BioTherapeutics position as of Q3 2021 after selling out during the quarter.
  • Red Door Wealth Management sold 2,000 Protalix BioTherapeutics shares in Q3 2021, an estimated $3K.
  • Red Door Wealth Management first reported a position in Protalix BioTherapeutics in Q2 2021 and held it in 1 quarter.
  • Red Door Wealth Management's Protalix BioTherapeutics position peaked at $3K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2021.

Based on Red Door Wealth Management's 13F filing for Q3 2021, filed 14 Oct 2021.